While the rate of inpatient colonoscopy has increased over the past decade and patients presenting with lower gastrointestinal bleeding (LGIB) tend to be sicker, the inpatient mortality rate has been dropping, according to an award-winning...
While the rate of inpatient colonoscopy has increased over the past decade and patients presenting with lower gastrointestinal bleeding (LGIB) tend to be sicker, the inpatient mortality rate has been dropping, according to an award-winning...
Dr Peery, from the University of North Carolina, discusses a study of the comparative effectiveness and harms of metronidazole-with-fluoroquinolone vs amoxicillin-clavulanate in treatment of diverticulitis among nonhospitalized patients.
Dr Peery, from the University of North Carolina, discusses a study of the comparative effectiveness and harms of metronidazole-with-fluoroquinolone vs amoxicillin-clavulanate in treatment of diverticulitis among nonhospitalized patients.
Dr Spiegel, director of health services research at Cedars-Sinai Medical Center in Los Angeles, discusses the persistent gastrointestinal symptoms seen in some patients after they recover from COVID-19.
Dr Spiegel, director of health services research at Cedars-Sinai Medical Center in Los Angeles, discusses the persistent gastrointestinal symptoms seen in some patients after they recover from COVID-19.
Anne Peery, MD, from the University of North Carolina, provides insight into the American Gastroenterological Association's recent update on the management of colonic diverticulitis.
Anne Peery, MD, from the University of North Carolina, provides insight into the American Gastroenterological Association's recent update on the management of colonic diverticulitis.
Vonoprazan offers an effective alternative treatment to intravenous proton pump inhibitors for prevention of rebleeding among patients with high-risk peptic ulcers, researchers found.
Vonoprazan offers an effective alternative treatment to intravenous proton pump inhibitors for prevention of rebleeding among patients with high-risk peptic ulcers, researchers found.
Results showed that a lower fibrosis stage (F0–1) was associated with a significantly reduced risk of cirrhosis and liver-related outcomes compared to patients with advanced fibrosis (F4).
Results showed that a lower fibrosis stage (F0–1) was associated with a significantly reduced risk of cirrhosis and liver-related outcomes compared to patients with advanced fibrosis (F4).
The U.S. Food and Drug Administration (FDA) on October 4 approved the Cologuard Plus multitarget stool DNA test for adults ages 45 and older who are average risk for colorectal cancer.
The U.S. Food and Drug Administration (FDA) on October 4 approved the Cologuard Plus multitarget stool DNA test for adults ages 45 and older who are average risk for colorectal cancer.